Why I'm Buying Cal-Maine Foods

The Setup

Cal-Maine Foods (NASDAQ: CALM) is the largest egg producer in the United States. Full stop. They produce, grade, package, and distribute shell eggs and egg-based products to retailers and foodservice customers nationwide. Their brand portfolio includes Eggland's Best, Land O'Lakes, Farmhouse Eggs, Sunups, and Crepini.

Over the past two years, CALM became a household name among investors for one reason: bird flu. The highly pathogenic avian influenza (HPAI) outbreak that began in 2022 devastated poultry flocks across the country, killing over 200 million birds by early 2026. The resulting supply shock sent egg prices to historic highs, and Cal-Maine's earnings went parabolic. The stock rode that wave to an all-time high of $113.99 in August 2025, eventually touching $126.40 on a 52-week basis.

Now, egg prices have crashed. Conventional white egg prices dropped roughly 70% from their peaks. Revenue is down 53% year-over-year. Earnings per share fell nearly 90%. And the stock sits at around $78 — down 38% from its highs.

The market has decided that the bird flu trade is over and moved on. I think that's exactly the wrong conclusion.

This Is Not Just an Egg Company Anymore

Here's what the market is missing: while everyone was focused on the bird flu windfall, Cal-Maine was using that cash to fundamentally restructure the business. The company that exists today is materially different from the commodity egg producer of two years ago.

The transformation shows up in one number: 52.9%. That's the share of Q3 fiscal 2026 net sales that came from specialty eggs and prepared foods — up from just 24% a year earlier. In a single year, Cal-Maine flipped its revenue mix from predominantly commodity eggs to majority higher-margin, more price-stable products.

This matters enormously. Commodity egg pricing is volatile and largely outside the company's control — it surges during supply shocks and collapses when flocks recover. Specialty eggs (cage-free, organic, pasture-raised, free-range) carry structured pricing and higher margins. Prepared foods (egg patties, omelets, scrambled eggs, wraps, pancakes) are value-added products with recurring demand and significantly lower price volatility.

Cal-Maine's CEO Sherman Miller framed it directly on the Q3 earnings call: the quarter was a real-time test of the company's strategy. Egg prices cratered, and yet the company still beat estimates on both the top and bottom line. That's not a fluke. That's a structurally different business proving itself in exactly the conditions that should have hurt it most.

The Numbers That Matter

Q3 fiscal 2026 (quarter ended February 28, 2026 — Cal-Maine\'s fiscal year ends in late May, so their calendar is offset from the standard year) was the quarter that scared away the tourists. Revenue dropped 53% to $667 million. Earnings per share fell 90% to $1.06. Gross margin compressed to 17.9%. Operating margin fell to 5.4%.

Those are ugly headline numbers. They're also exactly what you'd expect when egg prices drop 70% and the company is being compared against a quarter where HPAI was driving historic margins. The year-over-year comparisons are misleading because the prior year was anomalous — not this one.

Look beneath the surface and the story changes:

• EPS of $1.06 beat the consensus estimate of $0.78-$0.89. The company outperformed expectations in what was supposed to be a terrible quarter.
• Revenue of $667M beat the $642M estimate. Specialty and prepared foods carried the miss on conventional eggs.
• Net cash from operations was $103.6 million. The company is still generating real cash even in a down cycle.
• Year-to-date diluted EPS is $7.34 — down 59% from the prior year, but still a solid number for a stock trading at $78.
• Percent produced-to-sold increased to 91.5%, up 3.1 percentage points — meaning the company is relying less on outside egg purchases and controlling more of its supply chain.

The stock popped 5.3% on the earnings release. The market expected a disaster and got a beat instead. That's what happens when a company has quietly repositioned itself while nobody was paying attention.

The Acquisition Machine

Cal-Maine didn't waste the bird flu windfall. While competitors were simply cashing checks on inflated egg prices, Cal-Maine was deploying capital with surgical precision into acquisitions that would make the business more resilient and diversified on the other side.

Echo Lake Foods (~$258M, June 2025)

This was the big one. Echo Lake gave Cal-Maine a full prepared foods platform — production and distribution of ready-to-eat egg products and breakfast items like pre-cooked egg patties, omelets, waffles, and pancakes. This single acquisition is the primary driver behind the 441% prepared foods revenue surge. Cal-Maine has since launched a $15 million expansion project at Echo Lake and plans to grow prepared foods capacity by more than 30% over the next 18-24 months.

ISE America (~$110M, July 2024)

Added approximately 4.7 million laying hens across operations in Maryland, New Jersey, Delaware, and South Carolina. Expanded Cal-Maine's geographic footprint and production capacity on the East Coast.

Creighton Brothers & Crystal Lake ($128.5M, March 2026)

The most recent acquisition adds 3.2 million laying hens (including 500,000 cage-free), 865,000 pullets, a feed mill, 1,007 acres of land, and an egg products processing facility — all in Warsaw, Indiana, where Cal-Maine previously had no presence. Critically, Crystal Lake's liquid egg capacity gives Cal-Maine internal sourcing for key ingredients in its prepared foods business, reducing dependency on outside suppliers and improving margins.

They also invested $7 million into their Crepini Foods joint venture (which makes egg wraps and similar products), and Crepini's contribution to prepared foods revenue increased ninefold year-over-year. Cal-Maine even hired a dedicated Chief Financial Officer for Prepared Foods — a signal that this isn't a side project. It's a core strategic pillar.

The Bird Flu Card Nobody Wants to Hold

Here's the part the market has forgotten: bird flu hasn't gone away. It's still here. The HPAI virus remains widespread in wild bird populations across the country. The CDC confirmed as recently as March 2026 that the virus continues to cause outbreaks in poultry and dairy cattle, with sporadic human cases among agricultural workers.

The USDA reports that while detections in early 2026 are 56% lower than the same period in 2025, that still means 15.5 million birds were affected in January and February alone. Egg prices dropped 57% from their peaks as flocks recovered, but federal officials explicitly warn that seasonal risks remain elevated. Spring and fall migration — when wild birds spread the virus along major flyways — has historically triggered the worst outbreaks.

And the infrastructure to respond has arguably gotten worse, not better. Federal workforce cuts at USDA animal health labs have left critical positions unfilled, and the Congressional Research Service has raised concerns about weakened disease surveillance capabilities. Funding for international HPAI monitoring programs has been terminated, including surveillance of migratory birds in Central America that fly directly into U.S. poultry regions.

When it does, Cal-Maine is the single largest beneficiary in the public markets. They are the biggest egg producer in the country with the most diversified production base and the deepest supply chain. Supply shocks hit smaller producers harder and drive consolidation — which Cal-Maine has historically used to acquire distressed competitors at favorable prices.

Cal-Maine's own SEC filings acknowledge ongoing HPAI risk, noting that the virus impacted their flocks in fiscal 2024 and again in March 2026. They are not immune to the virus. But they are the best-positioned company to weather it and capitalize on the market disruption it creates.

The Valuation Case

Let's talk about what you're actually paying at $78.

A P/E of 5.44 for the dominant player in an essential food category with a proven earnings floor, active buyback program ($350.8 million remaining on a $500 million authorization), and a variable dividend policy that returned $0.36 per share just this quarter — payable May 14, 2026. Goldman Sachs recently raised their price target to $82 with a Neutral rating. I think that's conservative.

The market is pricing CALM as if the bird flu supercycle is permanently over and the company will revert to being a low-margin commodity producer. But the acquisitions, the mix shift, and the prepared foods buildout tell a completely different story. This is a company that used windfall profits to structurally improve its earnings quality — and the market hasn't caught up yet.

Even if bird flu never returns with the same severity, Cal-Maine at a 5x P/E with growing specialty and prepared foods revenue looks like a mispriced asset. If bird flu does return? This stock has demonstrated it can trade well above $100 on supply shock dynamics, and the next time it does, the underlying business will be significantly stronger than it was before.

What Could Go Wrong

No thesis is complete without the bear case, and I want to be honest about the risks:

• Egg prices could stay depressed longer than expected. If flock recovery accelerates and bird flu stays quiet through 2026, conventional egg margins may remain compressed for multiple quarters.
• Integration risk. Cal-Maine has made three major acquisitions in under two years. Echo Lake, ISE America, and Creighton Brothers all need to be integrated smoothly. Prepared foods capacity expansion could face delays or cost overruns.
• Variable dividend dependency. Cal-Maine's generous dividend is variable, not fixed — it's tied to earnings. If earnings continue to normalize downward, the yield will compress from its current elevated level.
• Consumer behavior shifts. Egg consumption per capita has been declining — from 286 eggs in 2020 to 271 in 2024. Some of this may be structural rather than purely price-driven.
• Regulatory and housing mandate costs. State-level cage-free mandates (like California's) require ongoing capital investment to convert production facilities.

These are real risks. But at a 5x P/E, I believe the market has already priced in a worst-case scenario, which creates an asymmetric setup: limited downside from here, with significant upside if any of the catalysts play out.

The Thesis

My investment thesis for Cal-Maine Foods is built on three pillars:

1. The Business Has Been Transformed

Specialty eggs and prepared foods now represent the majority of revenue. This isn't the same commodity egg company it was two years ago. The earnings floor is higher, the margin profile is improving, and management is investing aggressively to accelerate the shift. With 30%+ prepared foods capacity expansion planned, the mix will only improve from here.

2. The Valuation Is Disconnected from Reality

At ~$78, you're paying less than 6x trailing earnings for the dominant market leader in an essential food category, with a clean balance sheet, active buyback program, and a variable dividend that currently yields over 10%. The stock is pricing in permanent earnings impairment that the company's own results are actively disproving.

3. Bird Flu Is a When, Not an If

HPAI is endemic in wild bird populations. There is no vaccine. Federal surveillance capacity has been reduced. Spring and fall migrations create annual outbreak windows. The next supply shock is not a question of probability — it's a question of timing. When it happens, Cal-Maine is the single best-positioned public company to benefit, and the business underneath will be structurally stronger than it was during the last spike.

I'm buying at these prices because the market is offering me a chance to own the largest player in an essential industry, at a discount to its normalized earnings power, with a free option on a recurring supply shock catalyst. The downside is limited by the valuation floor and the improving business mix. The upside, if bird flu returns or the market recognizes the transformation underway, is substantial.

Sometimes the best investments are the ones nobody wants to talk about. Right now, nobody wants to talk about egg stocks. And that's exactly why I'm interested.